This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jeryl L. Hilleman Joins Ocera Therapeutics As Chief Financial Officer

SAN DIEGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl L. Hilleman has been appointed chief financial officer effective September 3, 2013. Ms. Hilleman will replace Dana McGowan who will continue with the company during a transition period in which the company plans to move its headquarters to Northern California.

"I am very pleased that an executive with Jeri's skills, global experience and proven expertise is joining our senior management team," said Linda Grais, M.D., president and chief executive officer of Ocera. "Her extensive public company experience, both in and outside of the biotech industry, combined with her operational leadership, will be invaluable as we execute on our immediate business priority to initiate a Phase 2b clinical trial of OCR-002 for the treatment of acute hepatic encephalopathy. I would also like to thank Dana McGowan for her many contributions and years of dedication to Ocera."

"Ocera has the potential to transform both acute and chronic treatment of critical liver conditions, with significant potential to save lives," said Jeri Hilleman. "The opportunity to join Ocera to help realize this potential is exciting and I'm pleased to be joining such a knowledgeable team."

Ms. Hilleman has over two decades experience as CFO of both private and public companies, including taking four companies public. Most recently, Ms. Hilleman has provided independent financial and strategic consulting for biotech and cleantech companies. From 2008 to 2012, Ms. Hilleman served as CFO of Amyris, Inc., a multi-national, renewable products company based in California and Brazil. Prior to Amyris, Ms. Hilleman served as CFO of Symyx Technologies, a public company selling instruments, software and research services to pharmaceutical and chemical companies, and led the finance function at two public biotechnology companies, Geron Corporation and Cytel Corporation. Ms. Hilleman is also a member of the board of directors and chair of the audit committee of Xenoport (Nasdaq:XNPT). Ms. Hilleman holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs